Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Moderna | Digital Realty Trust | Vistra | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | narrow The 10-K states that "the majority of our facilities operate as “merchant” facilities without long-term power sales agreements" and that Vistra is "not guaranteed any rate of return on our capital investments". Against that, the scarcity is real: six NRC-licensed nuclear units totalling 6,448 MW, licences running 2036-2053, inside a 43,641 MW fleet, plus 20-year PPAs with AWS (1,200 MW) and Meta (2,609 MW). The 2025 gas additions - Lotus (2,600 MW, closed October 2025) and pending Cogentrix (5,500 MW) - extend the merchant gas side, not the nuclear scarcity. Only the 433 MW of uprates extends the moat asset. |
| Moat type | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip The intangibles are non-replicable regulatory assets rather than patents: six nuclear licences (Comanche Peak 2050/2053, Perry 2046, Davis-Besse 2037, Beaver Valley 2036/2047), fuel "contracted to support all our refueling needs through 2030", section 45U credits "recognizing the value of existing carbon-free nuclear power", and TXU Energy, sold "for over 20 years" and "registered and protected by trademark law". Read 45U as a floor, not moat strength: the 2025 credit was $220m against $545m in 2024, and it "provides increasing levels of support as unit revenues decline". Efficient scale does not apply. |
| Leadership | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader Vistra describes itself as "one of the largest producers of power in deregulated markets in the U.S." with over 230 TWh generated, "one of the largest competitive power generators in the U.S. as measured by MWh of generation capacity", "one of the largest electricity generators in the U.S.", and "one of the largest competitive residential retail electricity providers". That hedged phrasing appears four times and is the strongest claim the filing makes. The 10-K names no competitor and assigns no rank, so co-leader is the ceiling the disclosure supports. |
| Pricing power | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | weak Vistra is a merchant price taker. Price formation rests on "the highest variable cost unit that clears the market", prices are "unpredictable and may fluctuate substantially", hedging markets have "limited liquidity after two to three years", and competing retailers "may offer different products, lower electricity prices and other incentives". ERCOT's $2,000/MWh figure is the low system-wide offer cap, applied conditionally when the peaker net margin exceeds three times CONE or under the PUCT Emergency Pricing Program, not a standing cap. PJM has "announced that it would propose" extending its capacity cap to 2028-29 and 2029-30, subject to FERC approval. |
| Summary | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Vistra's moat is one scarce asset wrapped in a commodity business. Six NRC-licensed nuclear units - 6,448 MW, licences running 2036-2053 - sit inside a 43,641 MW fleet that the 10-K says operates in the majority as "merchant" facilities with no long-term power sales agreements and no guaranteed rate of return. That block cannot be rebuilt by a rival, and is now partly de-risked by 20-year PPAs with AWS (1,200 MW from Comanche Peak) and Meta (2,609 MW from the PJM plants) plus section 45U credits. Everything else - 26,989 MW of gas, 8,743 MW of coal, the 5m-customer retail book - competes on price in markets Vistra does not set, against entrants the filing says keep building "despite relatively low power prices". The 2025 growth was gas M&A (Lotus, pending Cogentrix), which widens the commodity-exposed side. Narrow, for a specific reason: the moat is 15% of the fleet. |
| Chain position | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Merchant IPP: sells energy, capacity and ancillary services into ISO/RTO spot and short-term wholesale markets (ERCOT, PJM, ISO-NE, NYISO, CAISO, MISO) and resells to ~5m retail customers. Emerging role as long-term nuclear offtake supplier to hyperscalers (AWS, Meta). Not a price setter at any link. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |